Alcon: share rallies as more optimistic than expected
(CercleFinance.com) - -Swiss ophthalmology group Alcon has reported higher-than-expected Q1 results, leading it to expect full-year profits at the top end of its forecast range.
The former Novartis subsidiary last night announced sales that are up 7% at $2.3bn in Q1, including 11% growth at constant exchange rates.
Its operating margin also improved from 11.3% to 11.5% in the quarter, while core EPS rose from 68 cents to 70 cents.
The Basel-based company said it now expects to deliver 2023 EPS at the high end of its original target range of $2.55 to $2.65.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The former Novartis subsidiary last night announced sales that are up 7% at $2.3bn in Q1, including 11% growth at constant exchange rates.
Its operating margin also improved from 11.3% to 11.5% in the quarter, while core EPS rose from 68 cents to 70 cents.
The Basel-based company said it now expects to deliver 2023 EPS at the high end of its original target range of $2.55 to $2.65.
Copyright (c) 2023 CercleFinance.com. All rights reserved.